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Research letter
T-cell responses against 4-tert-butylphenol-
exposed pigmented cells in a patient with
occupational vitiligo
DOI: 10.1111/bjd.17713
DEAR EDITOR, Several case studies on contact or occupational
vitiligo after skin contact with 4-tert-butylphenol (4-TBP) have
been reported.1,2 Biochemical and cellular effects of 4-TBP on
melanocytes have been shown in vitro,3–6 but immunological
analyses explaining the immunizing ability of 4-TBP leading
to widespread vitiligo lesions beyond areas of primary contact
are still lacking. We report here the presence of a systemic
T-cell response to 4-TBP-exposed pigmented cells in a patient
with chemically induced vitiligo.
A 54-year-old man with Fitzpatrick skin type V presented with
vitiligo after contact of the hands and arms with the two-compo-
nent adhesive Armaflex, containing 4-TBP, during work as an
insulation installer at a shipyard (Fig. 1). He first developed der-
matitis at the contact sites, which depigmented 4 weeks later.
Although further contact with Armaflex adhesive was avoided, he
developed white patches on the dorsal site of his feet after wearing
plastic sandals. After 3 months the depigmented lesions were still
spreading beyond the contact sites and new white macules
occurred spontaneously on his chest (Fig. 1). The patient had a
family history of type 1 diabetes and early hair greying, but no
family history of vitiligo or thyroid disease.
Histopathology of a depigmented lesional skin biopsy
showed a normal epidermis with a dermal perivascular lym-
phocytic infiltrate, pigment-containing macrophages and the
absence of melanocytes. Patch tests with Armaflex and the
European Standard Series showed contact allergy to Armaflex
and to 4-TBP, followed by depigmentation of both patch test
areas 7 weeks later, with similar histopathology. Considering
the negative family history of vitiligo or thyroid disease, a
Koebner reaction by 4-TBP that reactivated a pre-existent
occult vitiligo seems unlikely. Three months of treatment with
topical tacrolimus followed by narrowband ultraviolet B ther-
apy for 6 months resulted in repigmentation of his face, but
not of the extremities. Afterwards, the vitiligo remained stable
for 3 years and was successfully treated by autologous punch
grafting. Nine years after initial contact with 4-TBP and the
onset of vitiligo, the disease was still stable, and blood
samples for immunological analyses were taken upon
informed consent.
Our in vitro analyses confirmed that 4-TBP inhibited melanin
synthesis in pigmented cells (data not shown).3 To investigate
the presence of systemic immunity against TBP-exposed mela-
nocytes, we stimulated peripheral blood T cells with autolo-
gous dendritic cells loaded with overnight 4-TBP-exposed
pigmented melanoma cells, as described previously for
monobenzone.7 Increased CD8+ T-cell reactivity against 4-
TBP-exposed cells was found in the patient, compared with a
panel of healthy donors (data available on request). In addi-
tion, moderate reactivity against unexposed cells was seen in
the patient, which may mediate the systemic spread of the
vitiligo to distant, unexposed body sites. The moderate levels
probably reflect the stable disease activity at the time of blood
sampling. The CD8+ T-cell response of the patient predomi-
nantly produced interferon-c upon 4-TBP stimulation, corre-
sponding to the T-cell responses found in vitiligo. No CD4+
T-cell reactivity was observed in the patient. Both CD8+ and
CD4+ T-cell reactivity to 4-TBP-exposed cells could be
induced in a healthy donor blood during 7 days of culture.
These T-cell responses were also reactive with the
keratinocyte cell line HaCaT exposed to 4-TBP, indicating
reactivity towards 4-TBP as a hapten in a contact dermatitis–
delayed-type hypersensitivity reaction (DTH),8 rather than
being pigment cell specific. DTH reactions are predominantly
mediated by CD4+ and CD8+ T-cell responses, found locally
in sensitized skin, followed by dampening of the response by
regulatory T cells producing interleukin (IL)-10. The depig-
mentation of the 4-TBP patch test site in the patient suggests
that contact sensitization by 4-TBP can increase the immuno-
genicity of pigmented cells leading to autoimmunity and
Fig 1. The patient with 4-tert-butylphenol-induced contact vitiligo.
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vitiligo. The potential TBP reactivity in patients with stable
vitiligo without a history of TBP exposure was not tested, as
occult exposure to (similar) phenols cannot be ruled out,
thereby obscuring conclusions on specificity.
The mechanism by which 4-TBP can induce vitiligo may
involve oxidative stress in melanocytes and apoptotic cell
death,3,4 resulting in the release of melanocyte antigens that
are taken up by dendritic cells. 4-TBP also activates the pro-
duction of IL-6, IL-8 and heat shock protein 70, key mole-
cules in the pathogenesis of vitiligo and other autoimmune
diseases.5,6 Presentation of melanocyte autoantigens by
activated dendritic cells can trigger a cytotoxic CD8+ T-cell
response against melanocytes, leading to vitiligo.
In conclusion, we have shown increased CD8+ T-cell reac-
tivity against pigmented cells upon 4-TBP exposure in a
patient with chemical-induced vitiligo. Our study adds to the
knowledge of 4-TBP as a provoking factor for vitiligo. These
findings emphasize the immunizing ability of 4-TBP against
pigmented cells and the risk of developing vitiligo upon
4-TBP exposure in susceptible individuals.
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